XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
  Drug Delivery
  Nanotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Biotechnology Channel
subscribe to Biotechnology newsletter

Latest Research : Biotechnology

   DISCUSS   |   EMAIL   |   PRINT
Grant Announced for Latest Software to Produce Blueprint of Designer Drug to Fight Influenza
Feb 22, 2005, 08:15, Reviewed by: Dr.

�Developing a blueprint for a new way of fighting influenza is a very important task," said Professor Williams.

�If we are successful, we will have taken important steps in finding a new way of fighting influenza and other diseases. It will then be for the pharmaceutical companies to take our blueprint and turn it into a drug.�


 
Chemists are shortly to begin using state-of-the-art computer technology to tackle deadly diseases such as influenza.

Researchers at the University of Bath have won a �261,000 grant to use the latest software to produce a blueprint of a designer drug that could stop influenza and some other diseases from replicating in humans.

The announcement of the grant comes at a time when fears are rising that an influenza outbreak developing from Asian chickens could kill thousands of people.

Professor Ian Williams, of the Department of Chemistry, will begin work in April on a project that could help pharmaceutical companies develop a better drug that could be taken by people coming down with flu to stop the disease developing.

The drug would work by being chemically very similar to part of the protective coating around the cells in our throats that the flu virus first attacks when a person becomes infected. The flu virus would be deceived into attacking the drug, called an inhibitor, instead of the cells.

The three-year project will be largely carried out by examining the behaviour of atoms of the influenza virus which attack cells, and atoms of the throat cells that are attacked. By using advanced software to model the way these atoms behave in highly complex interactions, the atomic structure of a suitable drug can be worked out.

Using computer modelling in this way can be of great assistance in drug design. Normally drugs are produced by trial and error in a process that can take many years.

Professor Williams and his colleague Dr Gus Ruggiero will use part of the grant from the Biotechnology and Biological Sciences Research Council to buy computers with a combined power many times that of the most advanced desktop machines.

This will be the first time the software, developed in Germany, will have been used in Britain. It will allow accurate modelling of the behaviour of tens of thousands of atoms, many times more sophisticated than previous work.

�Developing a blueprint for a new way of fighting influenza is a very important task," said Professor Williams.

�We often think of flu as just a nasty illness which puts us in bed for a few days. But some outbreaks can cause death on a large scale � the world-wide outbreak in 1918 killed more people than the First World War itself. We may now be facing another flu outbreak, this time originating from chickens in Asia.

�If we are successful, we will have taken important steps in finding a new way of fighting influenza and other diseases. It will then be for the pharmaceutical companies to take our blueprint and turn it into a drug.�

Professor Williams said that his work is a more sophisticated development from similar modelling which produced two anti-influenza drugs, Relenza and Tamiflu, whose effectiveness is limited.

He and Dr Ruggiero will study sialidases, enzymes used by the flu virus to snip off a special type of sugar, sialic acid, from the throat cell, allowing the virus to enter the cell and reproduce.

The new drug would be chemically similar to the sialic acid, but would act to inhibit the sialidase. This would hinder the virus from entering the cells, and from leaving them should they gain entry, thereby controlling the spread of the infection.

Because of similarities between the enzymes used by different viruses and bacteria, a similar approach may also be useful in fighting other diseases such as the South American sleeping sickness, Chagas Disease.
 

- University of Bath
 

University of Bath

 
Subscribe to Biotechnology Newsletter
E-mail Address:

 

For further information Tony Trueman can be contacted(e mail : [email protected]) at the University of Bath press office on 01225 384220 or 07966 341 322.

Related Biotechnology News

Gold Nanoparticle Molecular Ruler to Measure Smallest of Life�s Phenomena
Tiny inhaled particles take easy route from nose to brain
DNA Amplification and Detection Made Simple
Solitons Could Power Artificial Muscles
Nanoparticles could deliver multi-drug therapy to tumors
Nanotechnology can identify disease at early cellular level
Light-sensitive particles change chemistry at the flick of a switch
DNA Fragments for Making Tomatoes Taste Better Identified
'Custom' nanoparticles could improve cancer diagnosis and treatment
Human albumin from tobacco plants


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us